ClearPoint Neuro, Inc. (CLPT) Spending and interest coverage
- R&D / revenue · 12 months: Value 37.47%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 20.09%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 37.47% | Research and development expense / revenue. Period ending 2026-06-30. $15.84M ÷ $42.28M × 100 ≈ 37.47% |
| Stock-based compensation / revenue · 12 months | 20.09% | Share-based compensation / revenue. Period ending 2026-06-30. $8.49M ÷ $42.28M × 100 ≈ 20.09% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 15.84M USD | Research and Development Expense |
| Revenue | 42.28M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 8.49M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -31.04M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $15.84M | $42.28M | $8.49M | $-31.04M | (m) | 37.47% | 20.09% | (m) | (m) |
| 2026-03-31 | $15.04M | $40.61M | $8.49M | $-26.48M | (m) | 37.03% | 20.90% | (m) | (m) |
| 2025-12-31 | $13.90M | $36.97M | $8.18M | $-24.16M | (m) | 37.59% | 22.13% | (m) | (m) |
| 2025-09-30 | $13.99M | $34.33M | $7.90M | $-22.77M | (m) | 40.75% | 23.02% | (m) | (m) |
| 2025-06-30 | $13.86M | $33.59M | $7.78M | $-22.65M | (m) | 41.24% | 23.17% | (m) | (m) |
| 2025-03-31 | $13.15M | $32.24M | $7.31M | $-21.69M | (m) | 40.78% | 22.68% | (m) | (m) |
| 2024-12-31 | $12.39M | $31.39M | $6.91M | $-19.75M | (m) | 39.48% | 22.00% | (m) | (m) |
| 2024-09-30 | $11.71M | $30.43M | $6.75M | $-18.85M | (m) | 38.49% | 22.17% | (m) | (m) |
| 2024-06-30 | $10.83M | $28.07M | $6.43M | $-18.57M | (m) | 38.57% | 22.90% | (m) | (m) |
| 2024-03-31 | $11.31M | $26.16M | $6.28M | $-20.96M | (m) | 43.24% | 23.99% | (m) | (m) |
| 2023-12-31 | $11.71M | $23.95M | $6.08M | $-22.45M | (m) | 48.88% | 25.38% | (m) | (m) |
| 2023-09-30 | $11.98M | $22.32M | $5.71M | $-22.21M | (m) | 53.69% | 25.57% | (m) | (m) |
| 2023-06-30 | $12.21M | $21.70M | $5.30M | $-21.11M | (m) | 56.26% | 24.42% | (m) | (m) |
| 2023-03-31 | $11.02M | $20.95M | $4.53M | $-18.18M | (m) | 52.57% | 21.64% | (m) | (m) |
| 2022-12-31 | $10.89M | $20.55M | $4.13M | $-16.33M | $81.00K | 53.01% | 20.08% | -201.63× | Reported |
| 2022-09-30 | $10.05M | $19.66M | $3.88M | $-15.85M | (m) | 51.11% | 19.73% | (m) | (m) |
| 2022-06-30 | $10.13M | $19.09M | $3.29M | $-15.85M | $599.00K | 53.07% | 17.24% | -26.47× | Reported |
| 2022-03-31 | $9.96M | $17.30M | $2.66M | $-15.06M | $747.00K | 57.54% | 15.36% | -20.16× | Reported |
| 2021-12-31 | $8.98M | $16.30M | $2.08M | $-13.37M | $973.00K | 55.13% | 12.75% | -13.75× | Reported |
| 2021-09-30 | $8.16M | $15.73M | $1.48M | $-11.66M | $1.01M | 51.88% | 9.41% | -11.51× | Reported |
| 2021-06-30 | $6.74M | $14.68M | $1.19M | $-9.12M | $977.00K | 45.93% | 8.09% | -9.34× | Reported |
| 2021-03-31 | $5.43M | $13.74M | $1.18M | $-7.19M | $934.00K | 39.52% | 8.60% | -7.70× | Reported |
| 2020-12-31 | $4.69M | $12.83M | $1.09M | $-6.22M | $1.44M | 36.53% | 8.50% | -4.31× | Reported |
| 2020-09-30 | $3.74M | $12.32M | $985.59K | $-5.37M | $1.47M | 30.34% | 8.00% | -3.66× | Reported |
| 2020-06-30 | $3.29M | $11.73M | $911.52K | $-5.01M | $1.48M | 28.06% | 7.77% | -3.38× | Reported |
| 2020-03-31 | $3.17M | $11.86M | $874.49K | $-4.83M | $1.51M | 26.71% | 7.37% | -3.19× | Reported |
| 2019-12-31 | $2.92M | $11.22M | $799.11K | $-4.59M | $955.17K | 26.05% | 7.12% | -4.81× | Reported |
| 2019-09-30 | $2.53M | $10.28M | $838.90K | $-4.15M | $964.29K | 24.56% | 8.16% | -4.31× | Reported |
| 2019-06-30 | $2.38M | $9.16M | $980.84K | $-4.45M | $997.95K | 25.98% | 10.70% | -4.46× | Reported |
| 2019-03-31 | $2.35M | $8.20M | $1.14M | $-4.79M | $987.02K | 28.63% | 13.86% | -4.86× | Reported |
| 2018-12-31 | $2.31M | $7.35M | $1.23M | $-5.25M | $980.38K | 31.42% | 16.75% | -5.35× | Reported |
| 2018-09-30 | $2.41M | $6.76M | $1.60M | $-6.10M | $978.04K | 35.69% | 23.65% | -6.24× | Reported |
| 2018-06-30 | $2.38M | $6.67M | $1.42M | $-6.22M | $942.58K | 35.75% | 21.36% | -6.60× | Reported |
| 2018-03-31 | $2.80M | $7.00M | $1.29M | $-6.41M | $907.20K | 40.06% | 18.38% | -7.06× | Reported |
| 2017-12-31 | $2.81M | $7.38M | $1.25M | $-6.34M | $872.93K | 38.13% | 16.88% | -7.26× | Reported |
| 2017-09-30 | $2.76M | $7.34M | $838.61K | $-6.29M | $861.13K | 37.64% | 11.43% | -7.31× | Reported |
| 2017-06-30 | $2.86M | $7.23M | $889.73K | $-6.68M | $889.50K | 39.57% | 12.30% | -7.51× | Reported |
| 2017-03-31 | $2.53M | $6.36M | $906.33K | $-6.91M | $928.04K | 39.74% | 14.25% | -7.44× | Reported |
| 2016-12-31 | $2.63M | $5.75M | $959.59K | $-7.49M | $1.06M | 45.71% | 16.69% | -7.06× | Reported |
| 2016-09-30 | $2.62M | $5.63M | $997.85K | $-7.12M | $1.17M | 46.59% | 17.74% | -6.08× | Reported |
| 2016-06-30 | $2.41M | $5.26M | $1.03M | $-7.34M | $1.25M | 45.85% | 19.57% | -5.89× | Reported |
| 2016-03-31 | $2.09M | $4.98M | $1.56M | $-7.96M | $1.30M | 41.93% | 31.43% | -6.11× | Reported |
| 2015-12-31 | $1.96M | $4.59M | $1.68M | $-8.97M | $1.26M | 42.60% | 36.61% | -7.11× | Reported |
| 2015-09-30 | $2.14M | $4.04M | $1.75M | $-10.23M | $1.23M | 53.00% | 43.19% | -8.31× | Reported |
| 2015-06-30 | $2.54M | $3.43M | $1.67M | $-10.92M | $1.20M | 73.94% | 48.68% | -9.08× | Reported |
| 2015-03-31 | $3.01M | $3.79M | $1.08M | $-10.46M | $1.18M | 79.29% | 28.45% | -8.90× | Reported |
| 2014-12-31 | $3.30M | $3.60M | $880.76K | $-5.32M | $1.02M | 91.47% | 24.44% | -5.22× | Reported |
| 2014-09-30 | $3.27M | $3.82M | $1.01M | $-4.71M | $860.61K | 85.68% | 26.46% | -5.47× | Reported |
| 2014-06-30 | $3.13M | $4.12M | $1.18M | $-3.95M | $699.52K | 75.95% | 28.66% | -5.65× | Reported |
| 2014-03-31 | $2.97M | $3.49M | $1.32M | $-3.92M | $545.56K | 85.10% | 37.82% | -7.18× | Reported |
| 2013-12-31 | $2.92M | $3.93M | $1.46M | $-7.47M | $499.84K | 74.36% | 37.10% | -14.95× | Reported |
| 2013-09-30 | $2.97M | $4.62M | $1.38M | $-5.89M | $450.34K | 64.41% | 29.96% | -13.07× | Reported |
| 2013-06-30 | $2.82M | $4.82M | $1.54M | $-5.04M | $408.48K | 58.54% | 31.87% | -12.35× | Reported |
| 2013-03-31 | $2.57M | $5.34M | $2.12M | $-3.34M | $374.76K | 48.04% | 39.68% | -8.93× | Reported |
| 2012-12-31 | $2.48M | $5.06M | $2.03M | $-3.13M | $2.59M | 49.12% | 40.16% | -1.21× | Reported |
| 2012-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-12-31 | $4.25M | $3.82M | $989.90K | $-5.92M | $2.50M | 111.35% | 25.93% | -2.37× | Reported |
| 2011-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | $5.68M | $2.67M | $245.46K | $-9.52M | $1.59M | 212.82% | 9.20% | -5.98× | Reported |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sight Sciences, Inc. (SGHT) | United States | $0.478B | -9.95 |
| NeuroPace Inc (NPCE) | United States | $0.480B | -28.52 |
| CARLSMED, INC. (CARL) | United States | $0.405B | |
| Orthofix Medical Inc. (OFIX) | $0.373B | ||
| TACTILE SYSTEMS TECHNOLOGY INC (TCMD) | United States | $0.519B | 27.16 |
| CERUS CORP (CERS) | United States | $0.525B | -86.40 |
| Orchestra BioMed Holdings, Inc. (OBIO) | United States | $0.356B | -4.39 |
| SHOULDER INNOVATIONS, INC. (SI) | United States | $0.355B | |
| DELCATH SYSTEMS, INC. (DCTH) | United States | $0.558B | 820.33 |
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |